In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.
Last year (2018) was a record-setting year for approvals of new molecular entities (NMEs) by the FDA with 59 NMEs approved. DCAT Value Chain Insights examines the 2018 NME approvals, the product mix between small molecules and biologics, and which...
What is in store for CDMOs in 2019? A myriad of issues could impact market fundamentals and the recent highly favorable environment in which they have operated.
The year 2018 ended with a dizzying array of developments in the macroeconomic and...
Bristol-Myers Squibb’s pending $74-billion acquisition of Celgene would create a top 10 pharmaceutical company with combined revenues of more than $33 billion. At the JP Morgan Healthcare Conference being held in San Francisco this week,...
As the industry enters a new year, what will be key issues shaping the pharmaceutical industry in 2019? Coming off a record-setting year for new molecular entities approved by the FDA in 2018, will the industry be able to meet a new innovation bar...
A new DCAT benchmarking study surveyed executives from pharmaceutical companies, CDMOs, CMOs, and suppliers to answer this crucial question: is the pharma customer–supplier relationship in alignment? The study examines areas of critical interface:...
As 2018 comes to a close, what are key trends and emerging areas of interest for the pharmaceutical industry overall and in manufacturing? From new business models in healthcare delivery, to drug pricing, to digital transformation, to new...
Refining business strategies to respond to changing market conditions is a constant in any industry, including the pharmaceutical industry. As the industry enters the final month of 2018, which pharmaceutical company CEOs have made the mark thus...
What were the top developments shaping the pharmaceutical industry overall and the pharma manufacturing value chain in 2018? Takeda’s pending $62-billion acquisition of Shire, Cambrex’s $425-million acquisition of Halo Pharmaceuticals, a...
Emerging markets represent both opportunity and challenges for pharmaceutical companies. Risk management is an important component of any sourcing program, but with rising trade tensions and geopolitical uncertainty, managing supply lines and...
The pharmaceutical industry as a whole historically has had weaker working-capital performance comparative to other industries, but it is a key strategic goal overall for pharma companies and for sourcing and procurement organizations to improve...
